Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments

Neily Zakiyah, Maarten J Postma, Philip N Baker, Antoinette D I van Asselt, IMPROvED Consortium, Neily Zakiyah, Maarten J Postma, Philip N Baker, Antoinette D I van Asselt, IMPROvED Consortium

Abstract

Background: Pre-eclampsia is a pregnancy complication affecting both mother and fetus. Although there is no proven effective method to prevent pre-eclampsia, early identification of women at risk of pre-eclampsia could enhance appropriate application of antenatal care, management and treatment. Very little is known about the cost effectiveness of these and other tests for pre-eclampsia, mainly because there is no clear treatment path. The aim of this study was to provide a comprehensive overview of the existing evidence on the health economics of screening, diagnosis and treatment options in pre-eclampsia.

Methods: We searched three electronic databases (PubMed, EMBASE and the Cochrane Library) for studies on screening, diagnosis, treatment or prevention of pre-eclampsia, published between 1994 and 2014. Only full papers written in English containing complete economic assessments in pre-eclampsia were included.

Results: From an initial total of 138 references, six papers fulfilled the inclusion criteria. Three studies were on the cost effectiveness of treatment of pre-eclampsia, two of which evaluated magnesium sulphate for prevention of seizures and the third evaluated the cost effectiveness of induction of labour versus expectant monitoring. The other three studies were aimed at screening and diagnosis, in combination with subsequent preventive measures. The two studies on magnesium sulphate were equivocal on the cost effectiveness in non-severe cases, and the other study suggested that induction of labour in term pre-eclampsia was more cost effective than expectant monitoring. The screening studies were quite diverse in their objectives as well as in their conclusions. One study concluded that screening is probably not worthwhile, while two other studies stated that in certain scenarios it may be cost effective to screen all pregnant women and prophylactically treat those who are found to be at high risk of developing pre-eclampsia.

Discussion: This study is the first to provide a comprehensive overview on the economic aspects of pre-eclampsia in its broadest sense, ranging from screening to treatment options. The main limitation of the present study lies in the variety of topics in combination with the limited number of papers that could be included; this restricted the comparisons that could be made. In conclusion, novel biomarkers in screening for and diagnosing pre-eclampsia show promise, but their accuracy is a major driver of cost effectiveness, as is prevalence. Universal screening for pre-eclampsia, using a biomarker, will be feasible only when accuracy is significantly increased.

Figures

Fig. 1
Fig. 1
Selection of references in systematic review

References

    1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391–403. doi: 10.1016/j.bpobgyn.2011.01.006.
    1. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–e333. doi: 10.1016/S2214-109X(14)70227-X.
    1. Ngoc NT, Merialdi M, Abdel-Aleem H, Carroli G, Purwar M, Zavaleta N, et al. Causes of stillbirths and early neonatal deaths: data from 7993 pregnancies in six developing countries. Bull World Health Organ. 2006;84(9):699–705. doi: 10.2471/BLT.05.027300.
    1. National Advisory Body. Confidential enquiry into stillbirths and deaths in infancy report: 1998–1999. 8th Annual Maternal and Child Health Research Consortium. . 2001.
    1. Hyde C, Thornton S. Does screening for pre-eclampsia make sense? BJOG. 2013;120(10):1168–1170. doi: 10.1111/1471-0528.12309.
    1. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;7(342):d1875. doi: 10.1136/bmj.d1875.
    1. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010;203(4):383.e1–383.e8. doi: 10.1016/j.ajog.2010.06.014.
    1. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol. 2009;33(1):23–33. doi: 10.1002/uog.6280.
    1. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn. 2008;28(1):7–10. doi: 10.1002/pd.1890.
    1. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG. 2008;115(12):1465–1472. doi: 10.1111/j.1471-0528.2008.01902.x.
    1. Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199(2):122.e1–122.e11. doi: 10.1016/j.ajog.2008.01.013.
    1. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol. 2008;199(3):266.e1–266.e6. doi: 10.1016/j.ajog.2008.06.069.
    1. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012;119(7):778–787. doi: 10.1111/j.1471-0528.2012.03311.x.
    1. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension. 2014;64(3):644–652. doi: 10.1161/HYPERTENSIONAHA.114.03578.
    1. Odibo AO, Goetzinger KR, Odibo L, Cahill AG, Macones GA, Nelson DM, et al. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenat Diagn. 2011;31(10):990–994. doi: 10.1002/pd.2822.
    1. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010;56(4):741–749. doi: 10.1161/HYPERTENSIONAHA.110.157297.
    1. American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–1131. doi: 10.1097/01.AOG.0000437382.03963.88.
    1. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011; Available at: . Accessed Apr 1 2015.
    1. Walter E, Zehetmayr S. Guidelines for health-economic evaluations in Austria. Wien Med Wochenschr. 2006;156(23–24):628–632. doi: 10.1007/s10354-006-0360-z.
    1. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–283. doi: 10.1136/bmj.313.7052.275.
    1. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3. Oxford: Oxford University Press; 2005.
    1. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. Value Health. 2007;10(5):336–347. doi: 10.1111/j.1524-4733.2007.00187.x.
    1. World Bank. PPP conversion factor, GDP (LCU per international $). Available at: . Accessed Dec 18 2013.
    1. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;25(346):f1049. doi: 10.1136/bmj.f1049.
    1. Hadker N, Garg S, Costanzo C, Miller JD, Foster T, van der Helm W, et al. Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J Med Econ. 2010;13(4):728–737. doi: 10.3111/13696998.2010.535285.
    1. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 2008;12(6):iii-iv, 1–270.
    1. Shmueli A, Meiri H, Gonen R. Economic assessment of screening for pre-eclampsia. Prenat Diagn. 2012;32(1):29–38. doi: 10.1002/pd.2871.
    1. Simon J, Gray A, Duley L. Magpie Trial Collaborative Group. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie trial. BJOG. 2006;113(2):144–151. doi: 10.1111/j.1471-0528.2005.00785.x.
    1. Vijgen SM, Koopmans CM, Opmeer BC, Groen H, Bijlenga D, Aarnoudse JG, et al. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre-eclampsia at term (HYPITAT trial) BJOG. 2010;117(13):1577–1585. doi: 10.1111/j.1471-0528.2010.02710.x.
    1. Blackwell SC, Tomnlinson MW, Berman S, Redman ME, Hassan SS, Berry SM, et al. The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis. Prenat Neonatal Med. 2001;6:310.
    1. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn. 2011;31(1):66–74. doi: 10.1002/pd.2660.
    1. Walker JJ. Pre-eclampsia. Lancet. 2000;356(9237):1260–1265. doi: 10.1016/S0140-6736(00)02800-2.
    1. Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008;199(1):36.e1–36.e5. doi: 10.1016/j.ajog.2008.03.007.
    1. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol. 1988;158(1):80–83. doi: 10.1016/0002-9378(88)90782-X.
    1. Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM Modeling Good Research Practices Task Force Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—1. Value Health. 2012;15(6):796–803. doi: 10.1016/j.jval.2012.06.012.
    1. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202(2):161.e1–161.e11. doi: 10.1016/j.ajog.2009.09.016.
    1. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979–988. doi: 10.1016/S0140-6736(09)60736-4.
    1. Visser GH. Obstetric care in the Netherlands: relic or example? J Obstet Gynaecol Can. 2012;34(10):971–975.
    1. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–1890. doi: 10.1016/S0140-6736(02)08778-0.
    1. Gold M, Siegel J, Russell L, Weinstein M, editors. Cost-effectiveness in health and medicine. 1. Oxford: Oxford University Press; 1996.
    1. National Institute for Health and Care Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. 2010; Available at: . Accessed Apr 1 2015.
    1. Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early onset pre-eclampsia: the impact of aspirin after first trimester screening. Ultrasound Obstet Gynecol. 2015. Epub 2015 Feb 11.
    1. Godfrey KM, Inskip HM, Hanson MA. The long-term effects of prenatal development on growth and metabolism. Semin Reprod Med. 2011;29(3):257–265. doi: 10.1055/s-0031-1275518.
    1. Geelhoed JJ, Fraser A, Tilling K, Benfield L, Davey Smith G, Sattar N, et al. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon Longitudinal Study of Parents and Children. Circulation. 2010;122(12):1192–1199. doi: 10.1161/CIRCULATIONAHA.110.936674.
    1. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115(3):e290–e296. doi: 10.1542/peds.2004-1808.
    1. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki Birth Cohort Study. Stroke. 2009;40(4):1176–1180. doi: 10.1161/STROKEAHA.108.538025.
    1. Parkinson JR, Hyde MJ, Gale C, Santhakumaran S, Modi N. Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis. Pediatrics. 2013;131(4):e1240–e1263. doi: 10.1542/peds.2012-2177.
    1. Washburn L, Nixon P, Russell G, Snively BM, O’Shea TM. Adiposity in adolescent offspring born prematurely to mothers with preeclampsia. J Pediatr. 2013;162(5):912–917. doi: 10.1016/j.jpeds.2012.10.044.
    1. EURO-PERISTAT. European perinatal health report. 2013; Available at: . Accessed Dec 2014.
    1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–567. doi: 10.1016/S0140-6736(10)62037-5.
    1. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–825. doi: 10.1016/S0140-6736(11)60814-3.
    1. Hanson M, Gluckman P. Developmental origins of noncommunicable disease: population and public health implications. Am J Clin Nutr. 2011;94(6 Suppl):1754S–1758S. doi: 10.3945/ajcn.110.001206.
    1. Gordon FK, Ferguson EL, Toafa V, Henry TE, Goulding A, Grant AM, et al. High levels of childhood obesity observed among 3- to 7-year-old New Zealand Pacific children is a public health concern. J Nutr. 2003;133(11):3456–3460.
    1. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999–2008. Pediatrics. 2012;129(6):1035–1041. doi: 10.1542/peds.2011-1082.
    1. World Health Organization. Maternal health. 2013; Available at: . Accessed Dec 2014.
    1. United Nations. United Nations millennium development goals and beyond 2015. 2013; Available at: . Accessed Dec 2014.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera